Cancer News and Research

Latest Cancer News and Research

Trubion Pharmaceuticals to present data on its TRU-016 product candidate at the ASH meeting

Trubion Pharmaceuticals, Inc. announced today the acceptance of two data presentations on its product candidate, TRU-016, at the 2009 American Society of Hematology (ASH) Annual Meeting Dec. 5-8, 2009 in New Orleans, Louisiana.

12 Nov 2009

Gene therapy increases muscle size and strength with no adverse effects in monkeys: MDA

Four macaque monkeys that received injections of genes for a protein called follistatin into upper leg muscles experienced pronounced and durable increases in muscle size and strength and no adverse effects, the Muscular Dystrophy Association (MDA) announced today. The findings could have implications particularly for injured and aging people worldwide; and for tens of millions experiencing muscle loss associated with cancer, AIDs and muscle diseases.

12 Nov 2009

Stapled Peptides directly inhibit the Notch transcription factor complex

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, “Direct Inhibition of the Notch Transcription Factor Complex.”

12 Nov 2009

Resources to help understand stroke and carotid artery disease

The Society of Interventional Radiology offers numerous resources-including publications and the first-ever Catheter Lysis of Thromboembolic Stroke (CLOTS) course-for interventional radiologists, neuroradiologists, neurointerventionists, body interventionalists, and IR and INR fellows to aid in the understanding of stroke and carotid artery disease.

12 Nov 2009

Canadian researchers organize clinical trials to find new treatments for H1N1 infection

An important, ground-breaking initiative is unfolding in the global critical care community in response to the H1N1 pandemic.

12 Nov 2009

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it is developing ADCC TherasightTM, a novel theragnostic product that can help guide the drug development process and patient treatment protocols for the cancer therapeutic antibodies that use ADCC (antibody-dependent cellular cytotoxicity) as the major mechanism of action.

12 Nov 2009

Hoag Memorial Hospital Presbyterian named as the most preferred hospital by Orange County residents

For the 14th consecutive year, Hoag Memorial Hospital Presbyterian has been named the most preferred hospital by Orange County residents based on a consumer study by National Research Corporation (NRC). The award identifies hospitals that health care consumers in each region have selected as having the highest quality and image in over 300 markets throughout the U.S.

12 Nov 2009

Transplantation of hESC-derived OPCs spare spinal cord tissue in the cervical lesion site: Study

Geron Corporation today announced the publication of data showing that oligodendrocyte progenitor cells (OPCs) derived from human embryonic stem cells (hESCs), when transplanted into a rodent model of cervical spinal cord injury, reduced tissue damage within the lesion and improved recovery of locomotor function.

12 Nov 2009

Updated efficacy results from Allos Therapeutics' FOLOTYN study to be presented at the ASH meeting

Allos Therapeutics, Inc. today announced that abstracts from studies of FOLOTYN™ (pralatrexate injection) were accepted for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held at the Ernest N. Morial Convention Center in New Orleans, La., from December 5-8, 2009.

12 Nov 2009

Stapled Peptides can inhibit key intracellular biological targets, says new research

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival.

12 Nov 2009

54% of Americans are inconsistent in taking prescriptions, reveals survey

A new survey finds that 54 percent of Americans say they do not consistently take prescriptions as instructed even though 87 percent believe prescription medicines are important to their health – pointing to a growing public health problem.

12 Nov 2009

Nuvo Research announces new licensing agreement for Oxoferin

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a new licensing agreement for Oxoferin(TM), its topical wound healing agent, and additional details of the funding assistance to be provided by the Development Bank of Saxony for the development of WF10.

12 Nov 2009

Scientists report largest-ever collection of data about the proteins produced by genes in a single human organ

Scientists at a group of 11 research centers in China are reporting for the first time assembly of the largest-ever collection of data about the proteins produced by genes in a single human organ. Their focus was the liver, and their massive database in both protein and transcript levels could become a roadmap for finding possible new biomarkers and treatments for liver disease.

12 Nov 2009

IMS Health to launch comprehensive analytical tool for oncology market

IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the upcoming launch of IMS Oncology QuantifierTM, a comprehensive, clinically rich analytical tool that enables the company’s clients to assess treatment opportunities and guide commercial decisions in the $48 billion global oncology market.

12 Nov 2009

Scientists find way to disarm "undruggable" protein; discovery lays foundation for new kind of cancer therapy

Scientists have devised an innovative way to disarm a key protein considered to be "undruggable," meaning that all previous efforts to develop a drug against it have failed. Their discovery, published in the November 12 issue of Nature, lays the foundation for a new kind of therapy aimed directly at a critical human protein — one of a few thousand so-called transcription factors — that could someday be used to treat a variety of diseases, especially multiple types of cancer.

12 Nov 2009

Catheter-directed therapy: First-line treatment option for massive pulmonary embolism

Catheter-directed therapy or catheter-directed thrombolysis-an interventional radiology treatment that uses targeted image-guided drug delivery with specially designed catheters to dissolve dangerous blood clots in the lungs-saves lives and should be considered a first-line treatment option for massive pulmonary embolism, note researchers in the November Journal of Vascular and Interventional Radiology.

12 Nov 2009

Shimadzu, EDDA sign business deal

Shimadzu Corporation (Kyoto Japan) and EDDA Technology Inc. (Princeton, NJ, USA) today announced that both parties have entered into a business partnership on X-ray chest CAD systems based on the Radiography System of Shimadzu featuring its direct conversion flat panel detector (FPD) and EDDA's CAD applications.

12 Nov 2009

Researchers identify a new mechanism that inhibits the formation of new blood vessels

Researchers at Uppsala University, in collaboration with colleagues in Sweden and abroad, have identified an entirely new mechanism by which a specific protein in the body inhibits formation of new blood vessels. Inhibiting the formation of new blood vessels is an important aspect of, for example, cancer treatment. The study is published in the November issue of the journal Molecular Cancer Research.

12 Nov 2009

Study: Mouse gene uncovers new strategy for treating Alzheimer's disease

A new study reveals that a previously undiscovered mouse gene reduces the two major pathological perturbations commonly associated with Alzheimer's disease (AD). The research, published by Cell Press in the November 12 issue of the journal Neuron, finds that the novel gene interacts with a key cellular enzyme previously linked with AD pathology, thereby uncovering a new strategy for treating this devastating disorder.

12 Nov 2009

Researchers identify mouse gene that reduces the accumulation Alzheimer's plaques and tangles

Investigators at Burnham Institute for Medical Research (Burnham) and colleagues have identified a novel mouse gene (Rps23r1) that reduces the accumulation of two toxic proteins that are major players in Alzheimer's disease: amyloid beta and tau. The amyloid and tau lowering functions of this gene were demonstrated in both human and mouse cells.

12 Nov 2009

Cancer News and Research

Latest Cancer News and Research

Trubion Pharmaceuticals to present data on its TRU-016 product candidate at the ASH meeting

Gene therapy increases muscle size and strength with no adverse effects in monkeys: MDA

Stapled Peptides directly inhibit the Notch transcription factor complex

Resources to help understand stroke and carotid artery disease

Canadian researchers organize clinical trials to find new treatments for H1N1 infection

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

Hoag Memorial Hospital Presbyterian named as the most preferred hospital by Orange County residents

Transplantation of hESC-derived OPCs spare spinal cord tissue in the cervical lesion site: Study

Updated efficacy results from Allos Therapeutics' FOLOTYN study to be presented at the ASH meeting

Stapled Peptides can inhibit key intracellular biological targets, says new research

54% of Americans are inconsistent in taking prescriptions, reveals survey

Nuvo Research announces new licensing agreement for Oxoferin

Scientists report largest-ever collection of data about the proteins produced by genes in a single human organ

IMS Health to launch comprehensive analytical tool for oncology market

Scientists find way to disarm "undruggable" protein; discovery lays foundation for new kind of cancer therapy

Catheter-directed therapy: First-line treatment option for massive pulmonary embolism

Shimadzu, EDDA sign business deal

Researchers identify a new mechanism that inhibits the formation of new blood vessels

Study: Mouse gene uncovers new strategy for treating Alzheimer's disease

Researchers identify mouse gene that reduces the accumulation Alzheimer's plaques and tangles

Understanding the DNA Damage Response in Innate Immunity eBook

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Newsletters you may be interested in